Abbott Laboratories · NYSE:ABT
Abbott Laboratories — Merger or Acquisition (November 2025)
13 slides from Abbott Laboratories's merger presentation, Nov 20, 2025
Slide 1: Acquisition of Exact Sciences
Acquisition of Exact Sciences 20 | November | 2025
Slide 2: Information Related to This Communication
Information Related to This Communication Forward-Looking Statements This communication contains forward-looking statements about, among other things, the proposed acquisition of Exact Sciences by Abbott Laboratories (“Abbott”). Forward-looking statements involve substantial risks and uncertainties
Slide 3: We help people live their best lives through good health
A B B OT T ’ S P U R P O S E We help people live their best lives through good health ABBOTT PURSUES THIS PURPOSE BY: CANCER ~20 million (1) ~10 million (1) >2 million (2) – Improving health through Global new cancer Global cancer U.S. new cancer cases annually deaths annually cases annually innovat
Slide 4: Serving large, fast-growing areas of unmet need, with >$60 billion in TAM
E X A C T S C I E N C ES OV E RV I E W Serving large, fast-growing areas of unmet need, with >$60 billion in TAM in the U.S. alone (1) >$40 billion ~$5 billion >$15 billion Colon Cancer and Treatment Molecular Muti-Cancer Guidance TAM(1) Residual Disease Screening TAM(1) (MRD) TAM(1) (1) TAM: Total
Slide 5: Industry-leading products that help people throughout the cancer care continuum
E X A C T S C I E N C ES OV E RV I E W Industry-leading products that help people throughout the cancer care continuum CANCER CARE CONTINUUM Before After Cancer Diagnosis Cancer Diagnosis EXACT SCIENCES – Molecular residual disease (MRD) – Screening and surveillance TEST TYPES – Hereditary risk – Re
Slide 6: A leader in advanced cancer diagnostics
E X A C T S C I E N C ES OV E RV I E W A leader in advanced cancer diagnostics Precision Oncology $3.2 billion 2025 ESTIMATED REVENUE(1) SALES MIX 5+ million TESTS PERFORMED IN 2025 Screening 1.5+ million International ANNUAL TOUCHPOINTS WITH HEALTHCARE PROVIDERS ~1,300 | ~7,000 COMMERCIAL TOTAL EMP
Slide 7: Screening business
E X A C T S C I E N C ES OV E RV I E W Screening business REVENUE $ Billion 3.2 Cologuard® – colorectal cancer screening – Noninvasive test in the privacy of your home 2.8 Precision 2.5 Oncology – Revolutionized colorectal cancer screening – >$15 billion TAM; 20+ million tests performed since 2014 –
Slide 8: Precision Oncology business
E X A C T S C I E N C ES OV E RV I E W Precision Oncology business REVENUE $ Billion 3.2 Oncotype DX Breast® ; Oncotype DX Colon®; OncoExTra® (1) – Personalized treatment guidance tests 2.8 0.7 Precision 2.5 – Helps predict the likelihood of cancer reoccurrence and/or 0.7 Oncology the benefits speci
Slide 9: Positions Abbott at the forefront of the next era in diagnostics
S T R AT EG I C R AT I ON A L E Positions Abbott at the forefront of the next era in diagnostics • Scaled business, with accelerating growth and profitability • More preventative, predictive and personalized diagnostics • Large underpenetrated global segments • Attractive innovation pipeline to sust
Slide 10: Abbott becomes one of the leading cancer diagnostics companies in the world
F I N A NC I A L LY CO M P E L L I N G Abbott becomes one of the leading cancer diagnostics companies in the world, doubling its TAM to >$120B IMPACT TO ABBOTT (Annualized) (2) EXACT SCIENCES TOTAL ABBOTT ABBOTT’S DIAGNOSTICS SEGMENT $3+ billion 2025 ESTIMATED REVENUE (1) +50 basis points +300 basis
Slide 11: The premier global diagnostics company
A B B OT T A CQ U I S I T ION O F E X A C T S C I E N C E S The premier global diagnostics company 11
Slide 12: Transaction overview
A B B OT T A CQ U I S I T ION O F E X A C T S C I E N C E S Transaction overview • Exact Sciences shareholders will receive $105 per share in cash TERMS AND • Represents an equity purchase price of $21 billion; enterprise value of ~$23 billion TIMING • Transaction anticipated to close in 2Q 2026, su
Slide 13: 13
13
Abbott Laboratories — Merger or Acquisition (November 2025) on 6ix